The global ventilator-associated pneumonia market was valued USD 968.92 million in 2018 and is likely to grow at a 9.45% CAGR between 2019- 2025, according to the recent Market Research Future (MRFR) report. Ventilator-associated pneumonia or VAP is a kind of lung infection which affects people that are on ventilators. This is caused due to trauma, neurological diseases, and lung diseases.

Various factors are adding to the global ventilator-associated pneumonia market growth. Such factors, according to the new MRFR report, include increasing expenditure on R&D to develop an effective treatment for ventilator-associated pneumonia, rising cases of traumatic brain injury, and increasing prevalence of ventilator-associated pneumonia.

On the contrary, inappropriate reimbursement scenarios, high ventilator charges, and expensive diagnostic tests are factors that may limit the ventilator-associated pneumonia market growth over the forecast period.

Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/1377

Market Players

The key players actively participating in the growth of the global ventilator-associated pneumonia market are Adenium Biotech ApS, Nabriva Therapeutics AG, Merck & Co., Inc, AstraZeneca, and MedImmune. The Industry players are majorly focusing on acquiring new technologies to ease the process and bring effective methodologies dedicated to treatment.

Recent Players

According to the study presented by the US specialty chemicals company, Cumberland unveiled the superiority Of Vibativ® Over Vancomycin for selective patients suffering from bacterial pneumonia. Vibativ® (telavancin) is an FDA approved, patented anti-infective treatment of bacterial infections comprising ventilator-associated bacterial pneumonia and hospital-acquired. It discourses a range of gram-positive bacterial pathogens, comprising those that are considered multidrug-resistant and intricate-to-treat.

Market Segmentation

The global market for ventilator-related pneumonia is segmented based on diagnosis, mode of treatment, and end-user.

The ventilation-related pneumonia market is classified by Diagnosis into the following categories: clinical examination, radiological examination, microbiological analysis, and others.
The Mode of treatment segment is segmented into home care, hospital care, and others.
Based on the End-user, the global market is segmented into hospitals and clinics, outpatient care centers, research centers, and emergency medical services (EMS).
Regional Analysis

Based on the region, the global ventilator-associated pneumonia market report covers the recent trends & growth opportunities across Europe, the Asia Pacific (APAC), the Americas, and the Middle East and Africa (MEA). Among these, the Americas will spearhead the market over the forecast period for the increasing initiatives by non-government and government organizations for controlling the disease growth and rising prevalence of ventilator-associated pneumonia.

The global ventilator-associated pneumonia market in Europe is predicted to hold the second-largest share over the forecast period for the presence of well-developed healthcare industry and huge patient population having lung diseases.

Get Access Full Report @ https://www.marketresearchfuture.com/reports/ventilator-associated-pneumonia-vap-market-1377

The global ventilator-associated pneumonia market in the APAC region is predicted to grow at the fastest pace over the forecast period. The rising prevalence of ventilator-associated pneumonia and increasing initiatives undertaken by the non-government and government organizations for creating awareness are adding market growth.

The global ventilator-associated pneumonia market in the MEA is predicted to have the smallest share over the forecast period for increasing cases of infectious diseases and increasing government initiatives for the development of the healthcare industry.